Breast Cancer Diagnostic and Drug Technologies: Global Markets
The global market for Predictive Breast Cancer diagnostic and drug Technologies was valued at $23.4 billion in 2010 and came down to $21.2 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 2.5% and reach $24 billion by 2016.
SCOPE AND FORMAT
This report will provide an update and on overview on predictive testing in breast cancer diagnostics and drug technologies and global markets. The study’s objective is to review the tumor marker-based predictive companion tests and drugs for breast cancer, and then assess their global growth potential over a five-year period from 2011 to 2016. Review includes global markets for breast cancer incidence, current drugs, new developments, predictive diagnostic tests, market trends and new technologies, and developments and forecast trends for the use of current tests for better diagnosis and prognosis for breast cancer through 2016. Important tests, technologies and developments; market share by drug, test, current products on the market and market share by company or product; and statistical information for types of breast cancer prevalence globally, with special emphasis on the U.S. market, are discussed. The report focuses on tumor marker-based testing that provides vital information about the cancer. These tests can help determine the appropriate medicine and timing of treatment to address the disease most effectively. The report also includes current issues and trends affecting the industry. The report covers products in development, new technologies, trends, alliances, patents and mergers. It offers market data with respect to segments and geography. Other breast cancer detection and screening technologies and markets (e.g., mammography, ultrasound, biopsy) are not included in this report.
Usha Nagavarapu is a pharmaceutical professional with experience in scientific and alliance development. This includes more than 10 years of drug and device product development and alliance management experience. She has managed preclinical discovery programs from target identification through design of Phase I testing, including IND enabling studies, and assisted out-licensing and portfolio development activities. Strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early-start-ups to fulfill operational obligations while minimizing overall operational cost and burden.